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HIV-1 is characterized by high genetic variability, with implications for spread, and immune-escape 
selection. Here, the genetic modification of HIV-1 B subtype over time was evaluated on 3,328 pol and 
1,152 V3 sequences belonging to B subtype and collected from individuals diagnosed in Italy between 
2003 and 2016. Sequences were analyzed for genetic-distance from consensus-B (Tajima-Nei), non-
synonymous and synonymous rates (dN and dS), CTL escapes, and intra-host evolution over four 
time-spans (2003–2006, 2007–2009, 2010–2012, 2013–2016). Genetic-distance increased over time 
for both pol and V3 sequences (P < 0.0001 and 0.0003). Similar results were obtained for dN and dS. 
Entropy-value significantly increased at 16 pol and two V3 amino acid positions. Seven of them were 
CTL escape positions (protease: 71; reverse-transcriptase: 35, 162, 177, 202, 207, 211). Sequences with 
≥3 CTL escapes increased from 36.1% in 2003–2006 to 54.0% in 2013–2016 (P < 0.0001), and showed 
better intra-host adaptation than those containing ≤2 CTL escapes (intra-host evolution: 3.0 × 10−3 
[2.9 × 10−3–3.1 × 10−3] vs. 4.3 × 10−3 [4.0 × 10−3–5.0 × 10−3], P[LRT] < 0.0001[21.09]). These data 
provide evidence of still ongoing modifications, involving CTL escape mutations, in circulating HIV-1 
B subtype in Italy. These modifications might affect the process of HIV-1 adaptation to the host, as 
suggested by the slow intra-host evolution characterizing viruses with a high number of CTL escapes.
Human immunodeficiency virus type 1 (HIV-1) is characterized by a high genetic variability, mainly due to high 
rate of replication, mutation, and recombination1–3. Amino acid mutations that arise by chance can be thereaf-
ter selected by the pressure of the human immune system4,5 or combined antiretroviral therapy (cART)6,7. New 
selected amino acids may establish strong interactions among themselves, further modulating viral fitness, and 
development of drug resistance, but also immune escape process, thus enhancing pathogenic potential of the 
virus8,9.
Moreover, due to the continuum intent of HIV to find the best host adaptation, a constant selection of new 
viral species can occur at the intra-host level10. If these viral variants enhance viral competitive ability, they will 
rapidly spread at the epidemiological level becoming dominant variants characterized by selective advantage11,12.
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To date, literature on HIV-1 evolutionary dynamics focused attention on the spread of drug resistance and 
on the potential that drug resistant mutations, together with compensatory mutations, had on increased fit-
ness and virulence in patients never exposed to or starting cART13–15. Much has also been done in the field of 
CD8+ cytotoxic T-lymphocyte (CTL) related regions, their intra-host evolution and their relationship to clinical 
outcome16–18.
On the other hand, little is known regarding the extent of HIV-1 genetic modification over time, and regard-
ing the role that CTL-mediated selection pressure has in inter-host HIV-1 evolution, even if some evidence has 
recently emerged19,20. Moreover, if and how fixation of CTL escapes may influence viral load and immunological 
parameters in the first phases of infection is still largely unknown.
Thus, in the present study, we investigated the extent of genetic divergence, CTL escape prevalence and 
intra-host evolution of the most prevalent HIV-1 subtype, the B form, in a cohort of HIV-1 infected patients 
diagnosed in Italy between 2003 and 2016.
Results
Study population. A total of 3,328 HIV-1 B subtype infected individuals with at least one polymerase 
(pol) sequence at HIV-1 diagnosis (range of weeks between HIV-1 diagnosis and pol sequencing: 0.8–5.0) were 
retrieved for this study. V3 sequences collected at the same time point of pol were also available for a subgroup of 
patients (N = 1,152).
By dividing the population in accordance with year of HIV-1 diagnosis, 554 individuals belonged to the time 
frame 2003–2006, 826 to 2007–2009, 1,003 to 2010–2012, and 945 to 2013–2016 (Table 1).
Looking at the overall population, the majority of individuals were male (2,814, 84.6%), and Italian (2,603, 
78.2%) with a median (Interquartile-range, IQR) age of 38 (31–46) years. Among the risk factors, homosex-
ual and heterosexual contacts were the most prevalent infection routes (1,654 [49.8%] and 940 [28.2%], respec-
tively). Median (IQR) plasma viral load (copies/mL) was 76,619 (21,216–258,222), median (IQR) CD4+T and 
CD8+T cell counts were 333 (130–521) and 725 (460–1,085) (cell/mm3), respectively (Table 1). Recent infections 
accounted for 21.1% (N = 210) of the individuals for whom information regarding the chronic or recent phase of 
infection was available. The majority of these individuals with recent infection were male (180, 85.7%) and Italian 
(178, 84.8%) with a median (Interquartile-range, IQR) age of 36 (30–43) years. Homosexual and heterosexual 
contacts were the most prevalent infection routes (144 [68.6%] and 45 [21.4%], respectively). Median (IQR) 
Characteristic Overall 2003–2006 2007–2009 2010–2012 2013–2016 P-valuea
Number, n 3,328 554 826 1,003 945
Male, n (%) 2,814 (84.6) 443 (80.0) 696 (84.3) 875 (87.2) 800 (84.7) <0.0001
Year of first GRT, median (IQR) 2010 (2008–2013) 2005 (2004–2006) 2008 (2007–2009) 2011 (2010–2012) 2014 (2013–2015) —
Year of diagnosis, median (IQR) 2010 (2007–2013) 2005 (2004–2006) 2008 (2007–2009) 2011 (2010–2012) 2014 (2013–2015) —
Age at GRT, median (IQR) 38 (31–46) 38 (32–45) 38 (31–45) 38 (31–46) 39 (31–48) 0.358
Plasma viral load at GRT, (copies/mL), 
median (IQR) 76,619 (21,216-258,222) 82,285 (20,191–300,000) 64,958 (19,200-224,161) 81,421 (21,269-266,060) 78,434 (25,280-255,374) 0.131
CD4+T at GRT, (cells/mm3), median 
(IQR) 333 (130–521) 308 (110–500) 344 (136–521) 340 (132–535) 324 (141–512) 0.393
CD8+T at GRT, (cells/mm3), median 
(IQR) 725 (460–1085) 776 (511–1194) 807 (501–1137) 682 (429–1011) 697 (456–996) <0.0001
Time between diagnosis and GRT, 
(weeks), median (IQR) 2.0 (0.8–5.0) 2.7 (1.2–6.4) 2.3 (1.0–7.1) 1.8 (0.7–4.4) 1.4 (0.6–3.4) <0.0001
Origin, n (%)
  Italy 2,603 (78.2) 446 (80.5) 668 (80.9) 803 (80.1) 686 (72.6) <0.0001
  Europe 200 (6.0) 31 (5.6) 53 (6.4) 66 (6.6) 50 (5.3) 0.973
  Asia 34 (1.0) 5 (0.9) 9 (1.1) 12 (1.2) 8 (0.8) 0.929
  Africa 57 (1.7) 9 (1.6) 21 (2.5) 14 (1.4) 13 (1.4) 0.272
  North America 13 (0.4) 2 (0.4) 5 (0.6) 5 (0.5) 1 (0.1) 0.368
  South America 239 (7.2) 50 (9.0) 53 (6.4) 73 (7.3) 63 (6.7) 0.625
Unknown 181 (5.4) 10 (1.8) 17 (2.1) 30 (3.0) 124 (13.1) <0.0001
  Recent infectionsb, n (%) 210 (21.1) 51 (21.3) 69 (22.5) 58 (20.1) 32 (20.1) 0.618
Risk factor, n (%)
  Homosexual 1,654 (49.7) 268 (48.4) 404 (48.9) 538 (53.6) 444 (47.0) 0.599
  Heterosexual 940 (28.2) 184 (33.2) 266 (32.2) 270 (26.9) 220 (23.3) <0.0001
  Bisexual 190 (5.7) 22 (4.0) 26 (3.1) 60 (6.0) 82 (8.7) <0.0001
  Drug user 194 (5.8) 58 (10.5) 47 (5.7) 57 (5.7) 32 (3.4) <0.0001
  Other/unknown 350 (10.5) 22 (4.0) 83 (10.0) 78 (7.8) 167 (17.7) <0.0001
  Number of sequences in TCs, n (%) 1,119 (33.6) 109 (19.7) 285 (34.5) 391 (39.0) 334 (35.3) <0.0001
Table 1. Patients’ characteristic. aBy Kruskal-Wallis or Chi-squared test for trend, as appropriate. bInformation 
of chronic or recent infection was available for 994 individuals. GRT: Genotypic resistance test; IQR: 
Interquartile-range; TC: Transmission Clusters.
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plasma viral load (copies/mL) was 54,288 (13,077–189,192), median (IQR) CD4+T and CD8+T cell counts were 
535 (405–721) and 780 (582–1,237) (cell/mm3), respectively.
By looking at the four time spans, no statistically significant differences were observed with respect to demo-
graphic characteristics, with the exception of a slight increase in males, occurring in 2007–2009, and a slight 
decrease in Italians, in 2013–2016, and in heterosexuals, since 2010–2012 (Table 1). CD8+T cell count signifi-
cantly decreased in 2010–2012 and remained stable in 2013–2016 (Table 1).
Genetic distance evaluation over time. In the overall population, the mean value of genetic distance 
(mean ± standard error, SE) compared with consensus B was 0.043 ± 0.012 for pol and 0.100 ± 0.001 for V3. A 
progressive and significant increase in genetic divergence from consensus B was observed over time for both pol 
and V3 sequences (pol: from 0.037 ± 0.008 in 2003–2006 to 0.048 ± 0.010 in 2013–2016, P < 0.0001; V3: from 
0.090 ± 0.005 in 2007–2009 to 0.111 ± 0.003 in 2013–2016, P < 0.0001) (Figs 1A and 2A). Comparable results 
were obtained considering only the recent infections with available 210 pol and 66 V3 sequences, even if the statis-
tical significance was obtained only for pol (pol: from 0.039 ± 0.008 in 2003–2006 to 0.049 ± 0.010 in 2013–2016, 
P = 0.0003; V3: from 0.070 ± 0.010 in 2007–2009 to 0.090 ± 0.024 in 2013–2016, P = 0.315) (Figs 1B and 2B).
Similar results were also obtained for dN and dS values (overall dN and dS, mean ± SE for pol: 0.019 ± 0.006 
and 0.130 ± 0.043; overall dN and dS, mean ± SE for V3: 0.078 ± 0.001 and 0.129 ± 0.003). In particular, both dN 
and dS progressively increased over time in both pol and V3 sequences (pol: from 0.017 ± 0.005 and 0.109 ± 0.029 
in 2003–2006 to 0.021 ± 0.006 and 0.146 ± 0.037 in 2013–2016, P = 0.023 and 0.0001; V3: from 0.070 ± 0.004 
and 0.117 ± 0.008 in 2007–2009 to 0.086 ± 0.002 and 0.139 ± 0.005 in 2013–2016, P = 0.0006 and 0.056) (Table 2 
and Supplementary Material 1). Comparable results were again obtained considering only the recent infections 
(Table 2 and Supplementary Material 1).
Figure 1. Genetic distance of 3,328 (A) and 210 (B) HIV-1 B subtype pol sequences, belonging to newly 
diagnosed and recently infected patients, respectively, divided into four time frames in accordance with year of 
diagnosis. aGenetic distance was calculated by comparing sequences with HIV-1 consensus B using Tajima Nei 
model, MEGA 6. bBy Kruskal-Wallis test, corrected for Benjamini-Hochberg method. SE: standard error.
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Trend of amino acid variability over time. In order to measure the variation in pol and V3 amino acids 
over time, the first 369 amino acids of pol (99 PR amino acids and 270 reverse transcriptase [RT] amino acids) and 
the 35 amino acids defining the V3 were analysed for the entropy value. In particular, pol amino acid sequences 
obtained in the period 2003–2006 were compared with those obtained in the period 2013–2016. The same analy-
sis was performed for V3 amino acid sequences obtained in the period 2007–2009 and in the period 2013–2016.
Significant increases in entropy values were found at 18 positions (16 in pol and two in V3).
In particular, by comparing pol amino acid sequences, entropy increased at five amino acid positions in pro-
tease (PR: 19, 33, 71, 72, 79), and at 11 positions in RT (35, 162, 173, 174, 177, 196, 200, 202, 207, 211, 214) 
Figure 2. Genetic distance of 1,152 (A) and 66 (B) HIV-1 B subtype V3 sequences, belonging to newly 
diagnosed and recently infected patients, respectively, divided into three time frames. aGenetic distance was 
calculated by comparing HIV-1 sequences with HIV-1 consensus B using Tajima Nei model, MEGA 6. bBy 
Kruskal-Wallis test, corrected for Benjamini-Hochberg method. SE: standard error.
Year of 
diagnosis
Pol new diagnoses (N = 3,328) Pol recent infections (N = 210)
dN P-value dS P-value dN P-value dS P-value
2003–2006 0.017 ± 0.005
0.023
0.109 ± 0.029
0.0001
0.018 ± 0.005 0.023 0.018 ± 0.005
0.0001
2007–2009 0.018 ± 0.007 0.131 ± 0.062 0.019 ± 0.007 0.019 ± 0.007
2010–2012 0.019 ± 0.006 0.128 ± 0.031 0.019 ± 0.005 0.019 ± 0.005
2013–2016 0.021 ± 0.006 0.146 ± 0.037 0.021 ± 0.004 0.021 ± 0.004
Table 2. dN and dS parameters in accordance with the year of diagnosis in 3,328 and 210 HIV-1 B subtype 
pol sequences belonging to newly diagnosed and recently infected patients, respectively, divided into four time 
frames. dN and dS parameters (espressed as mean ± SE) were calculated by comparing sequences with HIV-1 
Consensus B by SNAP. Statistically significant differences were assessed by Kruskal-Wallis test, corrected for 
Benjamini-Hochberg method.
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(Fig. 3). Interestingly, CTL escape variants occur at seven of these positions, such as the PR position 71 (escape 
variant: A71V), and the RT positions 35 (escape variant: V35I), 162 (escape variant: S162ACQR), 177 (escape 
variant: D177E), 202 (escape variant: I202V), 207 (escape variant: Q207GE) and 211 (escape variant: R211K). By 
comparing V3 amino acid sequences, entropy increased at positions 2 and 19 (Fig. 3).
Entropy significantly decreased only at RT amino acid position 11 (delta entropy value: −0.122, P = 0.0001).
Trend of CTL escapes over time. By analysing the prevalence of CTL escape mutations in pol, we found 
that 8.7% of sequences (N = 288) did not contain escape mutations, 19.0% (N = 632) contained one escape, 26.2% 
(N = 872) contained two escapes, 23.0% (N = 767) contained three escapes, 13.9% (N = 462) contained four escapes, 
and 9.2% (N = 307) contained ≥5 escapes. Among recent infections, 8.6% of sequences (N = 18) did not contain 
escape mutations, 21.4% (N = 45) contained one escape, 30.0% (N = 63) contained two escapes, and 40.0% (N = 84) 
contained ≥3 escapes. Looking at the CTL escape prevalence over time, pol sequences with ≥3 CTL escapes rose 
from 36.1% in 2003–2006 to 54.0% in 2013–2016 (P < 0.0001). In particular, pol sequences with 3, 4 and ≥5 CTL 
escapes increased from 18.9%, 11.4%, and 5.8% in 2003–2006 to 25.3%, 16.5% and 12.2% in 2013–2016, P = 0.008, 
0.004, and <0.0001, respectively (Table 3). This increase was mainly due to PR escape mutation A71V, and RT escape 
mutations S162ACQR, D177E, I202V, and R211K (Supplementary Material 2). Limiting the analysis to recent infec-
tions, pol sequences with ≥3 CTL escapes were more frequently found in 2013–2016 compared with 2003–2006 
(56.2% vs. 31.4%), even if this increase did not reach statistical significance (P = 0.139) (Table 4).
By analysing significant patterns of pairwise correlations among pol CTL escape mutations, a positive signif-
icant correlation was found between the CTL escapes at position 162 (S162ACQR) and the escape at position 
177 (D177E) (number of sequences showing the correlated pair = 169; covariation frequency: 35.1%; phi = 0.11, 
P < 0.0001).
Figure 3. Amino acid positions characterized by an increased entropy value in the last time frame. Pol 
sequences obtained in the period 2003–2006 and those obtained in the period 2013–2016 were submitted for 
entropy analysis at HIV Los Alamos National Laboratory Entropy-Two tool (https://www.hiv.lanl.gov/content/
sequence/ENTROPY/entropy.html) in order to obtain delta entropy values. The same analysis was performed 
by comparing V3 sequences obtained in the period 2007–2009 and in the period 2013–2016. Only delta values 
≤0.10 and >0.10 followed by a P ≤ 0.05 after Benjamini-Hockberg correction were considered statistically 
significant.
Number of 
CTL escapes
Overall HIV-1 B subtype new diagnoses (N = 3,328)
P-value
2003–2006, 
N = 554, n (%)
2007–2009, 
N = 826, n (%)
2010–2012, 
N = 1,003, n (%)
2013–2016, 
N = 945, n (%)
0, N = 288 58 (10.5) 79 (9.6) 78 (7.8) 73 (7.7) 0.036
1, N = 632 130 (23.4) 168 (20.3) 188 (18.7) 146 (15.4) <0.0001
2, N = 872 166 (30.0) 213 (25.8) 277 (27.6) 216 (22.9) 0.012
3, N = 767 105 (18.9) 186 (22.5) 237 (23.6) 239 (25.3) 0.008
4, N = 462 63 (11.4) 105 (12.7) 138 (13.8) 156 (16.5) 0.004
≥5, N = 307 32 (5.8) 75 (9.1) 85 (8.5) 115 (12.2) <0.0001
Table 3. Prevalence of HIV-1 B subtype pol sequences with 0, 1, 2, 3, 4 and ≥5 CTL escape mutations, 
belonging to 3,328 newly diagnosed patients, divided into four time frames in accordance with year of 
diagnosis. Chi-squared test for trend, corrected for Benjamini-Hochberg method, were used to estimate 
significant changes over the four time periods.
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By analysing V3 loop, only 8 sequences in 1,152 (0.7%) contained CTL escapes. All these sequences belonged 
to the time frames 2010–2012 and 2013–2016 (2 [0.3%] and 6 [1.7%], respectively).
Role of epidemiological confounders in influencing HIV-1 B subtype variability and CTL escapes. 
We next sought to investigate whether changes in risk factors, in patients’ origin, and in sequences involved in 
transmission clusters (TCs) across time might interfere with HIV-1 B subtype increased variability.
Firstly, we investigated whether TCs frequency correlates with HIV-1 increased variability by comparing the 
subgroup of 1,119 pol sequences involved in TCs with the subgroup of 2,209 pol sequences out of TCs. The 
progressive and significant increase in genetic divergence from consensus B over time was confirmed both 
for sequences in TCs and for sequences out of TCs (TCs: from 0.038 ± 0.001 in 2003–2006 to 0.047 ± 0.00001 
in 2013–2016, P < 0.0001; out of TCs: from 0.037 ± 0.00001 in 2003–2006 to 0.048 ± 0.00001 in 2013–2016, 
P < 0.0001). Similar results were also obtained for dN and dS values (TCs: from 0.016 ± 0.0004 and 0.113 ± 0.003 
in 2003–2006 to 0.020 ± 0.0003 and 0.143 ± 0.002 in 2013–2016, P < 0.0001 and <0.0001; out of TCs: from 
0.017 ± 0.0003 and 0.107 ± 0.001 in 2003–2006 to 0.021 ± 0.0002 and 0.147 ± 0.002 in 2013–2016, P < 0.0001 
and <0.0001).
Looking at the CTL escape prevalence over time, pol sequences with 3, 4 and ≥5 CTL escapes increased both 
in TCs and out of TCs, although not always significantly (in TCs: from 24.0%, 8.3%, and 5.5% in 2003–2006 to 
28.1%, 14.7% and 14.4% in 2013–2016, P = 0.209; P = 0.060; P = 0.012; out TCs: from 17.5%, 12.1%, and 5.8% in 
2003–2006 to 23.7%, 17.5% and 11.0% in 2013–2016, P = 0.075; P = 0.020; P = 0.030).
In line with these results, the presence of TCs did not significantly affect either the number of circulating 
CTL escapes (Pearson’s phi = 0.015; P = 0.118) or the spread of single CTL escape (RT S162ACQR: phi = −0.25; 
P = 0.152; RT D177E: phi = 0.008; P = 0.641; RT I202V: phi = −0.051; P = 0.184; RT R211K; phi = −0.21; 
P = 0.221), with the exception of PR A71V (phi = 0.105; P < 0.0001).
Overall results suggest that the HIV-1 B subtype increased variability and the spread of CTL escapes are not 
predominantly correlated with expanding clades over time.
We next investigated whether variation in the proportion of risk factors, and patients’ origin across time might 
influence the HIV-1 B subtype increased variability. To do so, we restricted the analysis to a more homogenous 
population, composed of pol (N = 1,308) and V3 (N = 449) sequences belonging to MSM of Italian origin. The 
results confirmed the progressive and significant increase in genetic divergence from consensus B over time for 
pol, and like a trend for V3 (pol: from 0.038 ± 0.001 in 2003–2006 to 0.047 ± 0.001 in 2013–2016, P < 0.0001; V3: 
from 0.085 ± 0.007 in 2007–2009 to 0.098 ± 0.005 in 2013–2016, P = 0.348). Similar results were also obtained for 
dN and dS values (pol: from 0.017 ± 0.0004 and 0.110 ± 0.002 in 2003–2006 to 0.020 ± 0.0003 and 0.143 ± 0.002 
in 2013–2016, P < 0.0001 and <0.0001; V3: from 0.072 ± 0.007 and 0.093 ± 0.012 in 2007–2009 to 0.077 ± 0.004 
and 0.126 ± 0.010 in 2013–2016, P = 0.635 and 0.072). Looking at the CTL escape prevalence, pol sequences 
with 3, 4 and ≥5 CTL escapes were more frequently found in 2013–2016 compared with 2003–2006, even if this 
increase was not always significant (3 CTL escapes: from 20.8% in 2003–2006 to 26.6% in 2013–2016, P = 0.394; 4 
CTL escapes: from 11.6% to 14.6%, P = 0.224; ≥5 CTL escapes: from 5.8% to 14%, P = 0.018). Again, these results 
suggest that changes in risk factors and patients’ origin are not predominantly responsible for HIV-1 B subtype 
variability.
Impact of CTL escapes and year of diagnosis on HIV-1 pol evolution. A subgroup of 153 individ-
uals with two pol sequences available before therapy start (time-window between sequences within 70 weeks) 
was analysed to define if the evolutionary rate of HIV-1 per site per year may be affected by the time of diagnosis 
and number of CTL escapes. The evolutionary rate of HIV-1 per site per year in the 153 pairs of sequences was 
3.9 × 10−3 (3.3 × 10−3–4.5 × 10−3).
Among these pairs, 73 carried ≥3 CTL escapes (time-window between sequences, median weeks [IQR] 59 
[44–83]), while 80 carried ≤2 CTL escapes (time-window between sequences, median weeks [IQR] 62 [41–77]). 
Stratifying the pairs based on year of diagnosis, 28 pairs carrying ≥3 CTL escapes belonged to patients diag-
nosed after 2009 (time-window between sequences, median weeks [IQR] 58 [45–90]), while 57 carrying ≤2 CTL 
escapes belonged to patients diagnosed before 2009 (time-window between sequences, median weeks [IQR] 66 
[51–78]).
Rates of HIV-1 intra-host evolution (95% confidence interval, CI) were consistently lower in pairs containing 
≥3 CTL escapes than in those containing ≤2 CTL escapes (3.0 × 10−3 [2.9 × 10−3−3.1 × 10−3] vs. 4.3 × 10−3 
[4.0 × 10−3–5.0 × 10−3], P [likelihood-ratio test, LRT] < 0.0001[21.09]). Consistent with these data, the selective 
Number of 
CTL escapes
Overall HIV-1 B subtype recent infections (N = 210)
P-value
2003–2006, 
N = 51, n (%)
2007–2009, 
N = 69, n (%)
2010–2012, 
N = 58, n (%)
2013–2016, 
N = 32, n (%)
0, N = 18 3 (5.9) 7 (10.1) 5 (8.6) 3 (9.4) 0.640
1, N = 45 14 (27.4) 14 (20.4) 13 (22.4) 4 (12.5) 0.171
2, N = 63 18 (35.3) 17 (24.6) 21 (36.2) 7 (21.9) 0.521
≥3, N = 84 16 (31.4) 31 (44.9) 19 (32.8) 18 (56.2) 0.139
Table 4. Prevalence of HIV-1 B subtype pol sequences with 0, 1, 2, and ≥3 CTL escape mutations, belonging to 
210 recently infected patients, divided into four time frames in accordance with year of diagnosis. Chi-squared 
test for trend, corrected for Benjamini-Hochberg method, were used to estimate significant changes over the 
four time periods.
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pressure was lower in pol containing ≥3 CTL escapes than in pol containing ≤2 CTL escapes (dN/dS, 95% CI: 
0.28 [0.24–0.34] vs. 0.25 [0.22–0.29]).
Stratifying the pairs based on year of diagnosis, the rates of HIV-1 intra-host evolution (95% CI) were signif-
icantly lower in pairs containing ≥3 CTL escapes and belonging to patients diagnosed after 2009 than in those 
with ≤2 CTL escapes and belonging to patients diagnosed before 2009 (3.2 × 10−3 [3.0 × 10−3–4.0 × 10−3] vs. 
4.5 × 10−3 [4.0 × 10−3–5.0 × 10−3], P [LRT] < 0.001[12.76]). Again the selective pressure was confirmed to be 
lower in sequences circulating after 2009 and with ≥3 CTL escapes than in those circulating before 2009 and with 
≤2 CTL escapes (dN/dS, 95% CI: 0.21 [0.15–0.27] vs. 0.27 [0.23–0.32]).
These findings might suggest a better HIV-1 intra-host adaptation for most recent viruses driving a higher 
number of CTL escapes.
Correlation between pol CTL escape mutants and viro-immunological parameters. By analys-
ing a subgroup of 781 individuals characterized by recent infection or plasma viral load >10,000 copies/ml and 
CD4+T cells >500 cells/mm3, no significant correlations were found between CTL escapes and plasma viral load 
or CD4+T cell counts.
On the other hand, CD4/CD8 ratio significantly decreased in relation to the increased number of CTL escapes 
(from 1.64 ± 0.68 in patients infected by a virus with 0 CTL escapes to 0.69 ± 0.05 in patients infected by a virus 
with ≥5 CTL escapes, ρ = −0.100, P = 0.027) (Table 5). The negative correlations between the number of CTL 
escapes in pol and lower CD4/CD8 ratio were confirmed also when only the recent infections were analysed 
(1.02 ± 0.18 for 0 CTL escapes vs. 0.74 ± 0.06 for ≥3 CTL escapes, ρ = −0.15, P = 0.067) (Table 6).
Discussion
Our analysis based on HIV-1 B subtype pol (N = 3,328) and V3 (N = 1,152) sequences collected from a large 
number of HIV-1 newly diagnosed individuals in Italy in the time frame 2003–2016 indicates a progressive and 
significant increase in genetic and amino acid distance over time (with 18 amino acid positions characterized by 
entropy increase) for the most disseminated HIV-1 subtype in the world. This finding is also confirmed when 
only the subgroup of recently infected individuals is taken into account, confirming the higher variability of the 
new circulating viral strains belonging to HIV-1 B subtype compared with the older.
Despite the short time since its emergence (dated in 1944), HIV-1 B has generated successful epidemics in 
many countries in five continents, and the spread continues21. Due to the global extension of the HIV-1 B epi-
demic22–24, and the high evolutionary rates characterizing HIV25, a progressive diversity over time for this sub-
type has been reported both in North America20 and, even if limited to protease and integrase, in Europe26,27. A 
recent paper comparing the historic (1979–1989) versus modern (post-2000) HIV-1 subtype B cohorts in North 
America showed that in the past 30 years HIV-1 diversity increased approximately twofold, and the average back-
ground frequencies of CTL escape mutations also doubled20.
In our dataset, seven out of the 18 positions characterized by entropy increase take part in CTL escape variants 
(PR 71; RT 35, 162, 177, 202, 207, 211).
Number of 
CTL escapes
Plasma viral load, copies/ml, 
median (IQR) P-value
CD4+T cells, cells/
mm3, median (IQR) P-value
CD4/CD8 Ratio, 
mean ± SE P-value
0, N = 75 46,955 (26,054–139,500)
0.994* 0.667§
690 (536–816)
0.913* 0.912§
1.64 ± 0.68
0.034* 0.027§
1, N = 147 60,000 (21,670–223,238) 621 (535–764) 1.02 ± 0.15
2, N = 224 56,160 (23,296–170,885) 628 (542–764) 0.82 ± 0.05
3, N = 175 45,973 (162,295-125,728) 629 (539–777) 0.82 ± 0.05
4, N = 90 69,285 (24,275–262,493) 664 (560–800) 0.79 ± 0.07
≥5, N = 70 53,904 (18,213–205,785) 603 (549–695) 0.69 ± 0.05
Table 5. Correlation between CTL escape mutations and viro-immunological parameters belonging to 
781 individuals characterized by recent infection or by plasma viral load >10,000 copies/ml and CD4+T 
cells >500 copies/ml. *Statistically significant differences were assessed by Kruskal-Wallis test, corrected for 
Benjamini-Hochberg method. §Statistically significant differences were assessed by Spearman correlation. IQR: 
Interquartile-range; SE: standard error.
Number of 
CTL escapes
Plasma viral load, copies/ml, 
median (IQR) P-value
CD4+T cells, cells/
mm3, median (IQR) P-value
CD4/CD8 Ratio, 
mean ± SE P-value
0, N = 18 46,364 (36,589–93,896)
0.820* 0.442§
477 (395–720)
0.970* 0.708§
1.02 ± 0.18
0.309* 0.067§
1, N = 45 54,740 (17,168–371,500) 574 (430–728) 1.33 ± 0.41
2, N = 63 61,690 (13,125–184,514) 538 (429–697) 0.84 ± 0.11
≥3, N = 84 43,410 (9,767–231,416) 539 (407–777) 0.74 ± 0.06
Table 6. Correlation between CTL escape mutations and viro-immunological parameters belonging to 210 
recently infected patients. *Statistically significant differences were assessed by Kruskal-Wallis test, corrected for 
Benjamini-Hochberg method. §Statistically significant differences were assessed by Spearman correlation. IQR: 
Interquartile-range; SE: standard error.
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Of note, prevalence of CTL escapes significantly increased in the last time frame at five of these seven positions 
(PR: A71V; RT: S162ACQR, D177E, I202V, and R211K). Whereas entropy at positions 35 and 207 increased, V35I 
and Q207GE escapes did not change their prevalence concomitantly (V35I and Q207G/E prevalence: 18.8% and 
19.1% in 2003–2006 vs. 16.8% and 19.4% in 2013–2016, P = 0.672 and P = 0.119, respectively). The reason for the 
entropy increase at these 2 positions may thus reside in other amino acid mutations not involved in CTL escapes, 
such as V35LTM and Q207HNADRK, whose prevalence increased from 7.9% and 8.1% in 2003–2006 to 13.4% 
and 10.7% in 2013–2016, respectively (P = 0.034 and P = 0.048). The role of these amino acid mutations is not 
clearly demonstrated, and thus further studies might be necessary to define their impact on HIV-1 B evolution 
and pathogenesis.
Notwithstanding the increase in sequence diversity observed over time in our dataset, we have to consider 
that HIV variation and immune escape process are also limited by structural and functional constraints28,29. In 
particular, the virus would have fewer viable options to generate escape variants in conserved protein regions 
because of the fitness cost required30. However, HIV overcomes this problem thanks to specific mechanisms that 
compensate for the fitness costs. For example, studies on gag polyprotein demonstrated the selection of compen-
satory mutations, which can restore the viral fitness. These mutations can occur both within31 and outside the 
epitope, but nearby in the three-dimensional protein structure32,33.
In this respect, the increased prevalence of some amino acid variants in pol and their correlation in mutational 
pathways (such as for S162ACQR and D177E) may suggest a compensatory role played by these mutations, which 
can therefore explain their frequent occurrence, rather than by chance in the circulating viral population. Its effect 
may positively influence the fixation of a specific CTL escape at population level34. In line with this, the preva-
lence of sequences with ≥3CTL escapes progressively increased in both overall population and recent infections, 
reaching 54.0% and 56.2% in 2013–2016, respectively. This may represent an evolutionary advantage with conse-
quences for disease progression, infectivity, transmissibility, and response to antiviral treatments35.
Moreover, the ability of HIV-1 immune escape mutations to accumulate rapidly could undermine host anti-
viral immunity36–38, and thus in turn have immunological consequences at population level. In this respect, our 
study found that the higher number of CTL escapes in pol frequently correlated with lower CD4/CD8 ratio (delta 
CD4/CD8 ratio = −0.95) at HIV-1 diagnosis, suggesting an increased pathogenic potential of these viral strains. 
However, these data need to be interpreted with caution, especially because of the lack of HLA information.
The impossibility to match CTL escape variants with HLA types of the host also represents a limitation for 
the estimation of the CTL escape prevalence. It is known that CTL escape prevalence may differ between HLA 
mismatched and HLA matched people39,40, and that the fixation of some HIV-1 polymorphisms at population 
level strongly depends on population characteristics41. To partially overcome the lack of HLA information, we 
have focused attention on those CTL escapes that significantly increased over time, such as the PR A71V and 
the RT D177E (related to HLA-B*1503), the RT S162ACQR (related to HLA-A*1101 –A*8601, -A*0301, -B*38 
and B*0702), I202V (related to HLA-B4001), and R211K (related to HLA-A*2501). By matching these data with 
the prevalence of HLA in Italian population, we found that all the mentioned HLA are well represented in Italy. 
In particular, the HLA-A*1101, -A*2501 and -A*0301 represent 16% of the overall HLA-A locus, while the 
HLA- B*5101, -B*0702, -B*4001, and -B*03 16% of the overall HLA-B locus42. Thus, the spread of the previously 
mentioned CTL escape polymorphisms at the population level in Italy may be explained by the relative diffusion 
of matched HLA in the general Italian population.
However, the persistence of CTL escapes is not always dependent on matched HLA. Specific escape muta-
tions persist upon transmission to HLA unmatched hosts, perhaps owing to a lack of fitness costs43,44. A recent 
mathematical model shows that the median time to escape in HLA matched individuals across the 26 epitopes 
considered is 8 years, and the reversion rates is a little slower (median time to reversion: 6.5 years) with no evi-
dence of reversion in 56% of CTL epitopes, suggesting that CTL escapes are able to spread rapidly at population 
level independently of HLA45.
The role of CTL escapes in the process of HIV adaptation to the host was also confirmed by the estimation of 
the intra-host evolution. In particular, by analysing a subgroup of individuals with two pol sequences available, we 
found that the rate of intra-host evolution and the consequent selective pressure were significantly lower for most 
recent HIV-1 diagnoses carrying ≥3 CTL escapes than older diagnoses carrying fewer CTL escapes (3.2 × 10−3 vs. 
4.5 × 10−3). In the context of the already known slow HIV-1 pol evolution46, the slower intra-host evolution found 
for most recent circulating viruses driving a higher number of CTL escapes may suggest that HIV-1 had improved 
its adaptation to the host in recent years compared with the past, even if the adaptation process is still occurring.
Besides CTL escapes, further attention should be given to neutralizing epitope escapes, of which the V3 loop 
is rich. In our study, we found that while in pol entropy values increased also within CTL epitopes (such as PR 
position 71 and the RT positions 35, 162, 177, 202, 207 and 211), in V3 higher mutation rates occurred almost 
exclusively within previously described neutralizing epitopes47, and at residue 19 already associated with R5 tro-
pism48. We are conscious that our analysis is limited to a very short region of env, and that further studies taking 
into account a longer env fragment encompassing at least all the variable loops and conserved regions of gp120 
may be necessary. Similar studies will be of extreme interest in defining the tracing of amino acid modifications 
in HIV-1 domains involved in vaccine strategies and co-receptor affinity.
Looking at potential epidemiological confounders able to influence HIV-1 B subtype variability and CTL 
escapes over time, we found that neither risk factor nor patients’ origin, nor TCs strictly (and exclusively) impact 
HIV-1 B subtype variability over time. Doing these sub-studies yielded results mainly consistent with the overall 
analysis, suggesting that HIV-1 B subtype varied over time, regardless of these confounders.
Nevertheless, we cannot definitely exclude that the relevant epidemiological changes occurring in Italy in 
recent years, such as the migratory waves from low-middle income areas49, or the time-dependent influx of 
sequences from different risk groups might contribute (even if not predominantly) to HIV-1 B subtype variation 
in this country. For example, in our dataset individuals of “unknown” origin and “other or unknown” risk factors 
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increased from 1.8% and 4.0% in 2003–2006 to 13.1% and 17.7% in 2013–2016, while Italians and heterosexuals 
decreased from 80.5% and 33.2% in 2003–2006 to 72.6% and 23.3% in 2013–2016. This geographic and epidemi-
ological admixture combined with the documented high rate of post-immigration HIV-1 acquisition50 might also 
favour the diffusion of new HLAs at population level and the selection of new CTL escape mutations.
Finally, as the article is mainly focused on pol, the introduction of antiretroviral therapies merits attention 
(RT inhibitors were introduced in the late 1980s and PR inhibitors in the mid 1990s). Indeed, two out of the 
18 positions characterized by entropy increase, the PR 33 and 71, are involved in drug resistance. The observed 
entropy increase was mainly due to the mutations L33F/I and A71VTIL, whose prevalence increased in the last 
two time frames (L33FI: 0.4% in 2003–2006 vs.1.2% in 2007–2009 vs. 3.9% in 2010–2012 vs. 3.0% in 2013–2016, 
P < 0.0001; A71VTIL: 15.0% in 2003–2006 vs. 13.7% in 2007–2009 vs. 18.5% in 2010–2012 vs. 21.2% in 2013–
2016, P < 0.0001). Both L33F and A71VTIL are PI-selected accessory mutations, associated with a minimal or 
null reduced susceptibility to PIs51,52. Even if some of these mutations such as L33I and A71VT may also appear 
as natural polymorphisms or CTL escapes (such as A71V), we cannot exclude that their increased prevalence in 
the last two time frames may be an indicator of viral adaptation to PI drug exposure.
In conclusion, this study, based on HIV-1 B subtype sequences diagnosed in Italy, provides additional evi-
dence that HIV-1 is still adapting to host, and that this adaptation may include CTL escape mutations. These 
findings can help in making accurate maps of escape pathways and in defining optimal induction CTLs strategies 
that may be effective in controlling HIV-1 replication, which may have implications for immunotherapeutic inter-
ventions. Moreover, this paper poses the bases for further studies involving viral evolution and viral adaptation 
focused on rapidly expanding epidemics such as those currently occurring in Africa and Asia, mainly driven by 
recombinant forms and non-B pure forms.
Materials and Methods
Study population. This study was conducted on 3,328 pol sequences (containing the full-length PR and 
the first 270 RT codons; nucleotides length: 1,107) and 1,152 V3 sequences (nucleotides length: 105; amino acid 
length: 35) obtained from HIV-1 B subtype newly diagnosed infected individuals (one sequence per patient) in 
Italy. All patients were naïve to cART and 210 of them were HIV-1 recently infected. Pol and V3 sequences were 
performed from plasma samples for routine clinical purposes from 2003 to 2016 and from 2007 to 2016, respec-
tively, immediately after the diagnosis, and then collected in an anonymous database53,54. HIV-1 B subtype for 
pol and V3 sequences was firstly determined by Stanford DB (https://hivdb.stanford.edu/) and geno2pheno algo-
rithm (https://coreceptor.geno2pheno.org/), respectively, and further confirmed by phylogenetic analysis based 
on pol, as described previously55.
Recent infections were determined by: (i) clinical/laboratory signs of primary HIV infection (HIV-1 plasma 
viral load levels >10,000 copies/mL and negative or indeterminate HIV-1 antibody test); (ii) a documented neg-
ative HIV-1 test performed within the 6 months prior to the HIV-1 diagnosis; and (iii) an antibody avidity index 
≤0.80 (test performed only in clinically AIDS free individuals)56,57.
Ethic statement. This study was conducted on data collected for clinical purposes. All data used in the 
study were previously anonymized, according to the requirements set by Italian Data Protection Code (leg. decree 
196/2003) and by the General authorizations issued by the Data Protection Authority. This study was approved by 
the ethics committee of Tor Vergata Hospital (Ethics Approval No. 238/16, 14 December 2016) and L. Spallanzani 
National Institute for Infectious Diseases, IRCCS (Ethics Approval No. 51, 18 December 2003).
Genetic distance and non-synonymous and synonymous substitution rate estimation. Genetic 
distance between each pol and V3 sequence and the HIV-1 subtype B consensus sequence was evaluated using 
MEGA 6 program based on the Tajima Nei model46,58.
The HIV-1 subtype B consensus sequence used for this analysis was published in 2002 by Los Alamos HIV 
Database. This consensus can be retrieved at https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html 
site. The consensus sequence was calculated according to the default values on the Consensus Maker tools. Details 
can be retrieved at https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html#consensus.
Mean number of synonymous (dS) and nonsynonymous (dN) substitutions per site were calculated by the 
method of Nei and Gojobori59, through the automatic tool SNAP (https://www.hiv.lanl.gov/content/sequence/
SNAP/SNAP.html).
CD8+ cytotoxic T-lymphocyte (CTL) escape mutations. Prevalence of CTL escape mutations in each 
pol and V3 sequence was evaluated considering all variants in the Los Alamos Immunology Database list defined 
as: documented escape, or non-susceptible form, or calculated escape, or inferred escape, or diminished response 
escape (https://www.hiv.lanl.gov/content/immunology/variants/ctl_variant.html, Data last updated at 2017-03-
09, Supplementary Material 3).
To identify potential patterns of pairwise correlations between specific CTL escape mutations, a binomial 
correlation coefficient (phi) and its statistical significance for each pair of mutations were calculated. Average 
linkage hierarchical agglomerative cluster analysis was performed to investigate potential evolutionary pathways 
among CTL escape mutations60.
Shannon Entropy calculation. In order to evaluate the variability of each amino acid site in pol over time, 
the first 369 amino acids of pol (99 PR amino acids and 270 RT amino acids) were analysed for the entropy 
value. In particular, amino acid sequences obtained in the period 2003–2006 and those obtained in the period 
2013–2016 were submitted to HIV Los Alamos National Laboratory (LANL) Entropy-Two tool (https://www.hiv.
lanl.gov/content/sequence/ENTROPY/entropy.html)61. The same analysis was performed by comparing entropy 
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values at the 35 amino acid positions of V3 sequences obtained in the period 2007–2009 and in the period 2013–
2016. Only delta values ≤0.10 and >0.10 followed by a P ≤ 0.05 after Benjamini-Hochberg correction62 were 
considered statistically significant.
Statistical analysis. In order to estimate differences in demographic, virological and immunological param-
eters, genetic distance and CTL escape prevalence over time, pol sequences were divided into four time spans 
in accordance with the year of diagnosis (time spans: 2003–2006, 2007–2009, 2010–2012, 2013–2016). For the 
same purposes, V3 sequences, available from 2007, were divided into three time spans (time spans: 2007–2009, 
2010–2012, 2013–2016).
CTL escapes were divided into 6 pre-defined categories (0, 1, 2, 3, 4, and ≥5 CTL escapes) for the overall pop-
ulation and into 4 pre-defined categories (0, 1, 2, and ≥3 CTL escapes) for recently infected individuals.
Genetic-distance, dN and dS values, and number of CTL escapes were also evaluated in 1) the subgroup 
of 1,308 pol and 449 V3 sequences belonging to MSM of Italian origin, 2) the subgroup of 1,119 pol sequences 
involved in TCs compared with the subgroup of 2,209 pol sequences out of TCs for the purpose of investigating 
whether risk factors, patients’ origin, and sequences in TCs across time might interfere with obtained results. 
Potential TCs (defined as clusters of ≥3 pol sequences) were identified by HIV-TRACE using a Tamura-Nei 
model, and a genetic distance cut-off ≤0.01563.
Kruskal-Wallis and Chi-squared test for trend were used to estimate significant changes over time periods, 
while Pearson’s Chi-squared test and Mann Whitney test were used to estimate significant changes between two 
different time periods.
Spearman correlation and Kruskal-Wallis test were also used to estimate significant correlations between 
viro-immunological parameters and number of CTL escapes. In order to ensure, wherever possible, exclusion 
of individuals with a late diagnosed chronic infection, these analyses were restricted to a subgroup of 781 indi-
viduals including the documented recent infections (N = 210) and individuals characterized by plasma viral load 
>10,000 copies/ml and CD4+T cells >500 cells/mm3 (N = 571). Viral load and CD4+T cells cut-offs were cho-
sen in accordance with Pantazis N. et al. Lancet HIV 201464.
Again, only P ≤ 0.05 after Benjamini-Hochberg correction62 were considered statistically significant.
All the analyses were performed using the R open source statistical environment (version 3.3.1) and SPSS 
(version 23) for Windows (SPSS Inc., Chicago, Illinois).
Evolutionary rate estimation. To determine if year of diagnosis and number of CTL escapes may affect 
the intra-patient evolutionary rate of HIV-1, a subgroup of 153 patients with two pol sequences available before 
therapy initiation (time-window between sequences within 70 weeks) were analyzed by using HyPhy pol evolu-
tion package65. All sequences from each patient were arranged chronologically and the probability of evolving 
from the oldest to the newest sequence was estimated using maximum likelihood method. In particular, the pol 
sequences of individuals diagnosed after 2009 and with ≥3 CTL escapes were compared with pol sequences of 
individuals diagnosed before 2009 and with ≤2 CTL escapes. Branch lengths between the two sequences were 
assigned based on the difference between sampling dates. For each individual, we determined the nucleotide 
substitution rate by using a General Time Reversible (6 substitution rates, empirical frequencies) model, assum-
ing strict molecular clock. Significance was assessed using the likelihood ratio test (LRT) with N-2 degrees of 
freedom. The evolutionary rate per site per year within host were tested for equality using the likelihood-ratio test 
(LRT)66. Sequence data are available in the Supplementary Dataset 1.
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